CF PharmTech (02652) has announced that it recently received voluntary undertakings from Dr. Liang Wenqing, co-founder, chairman, executive director, and chief executive officer, and Dr. Li Li, co-founder, executive director, and chief scientific officer, based on their confidence in the group's long-term development prospects and long-term value.

Under the undertakings, the core management has voluntarily committed to further extending the lock-up period on shares beneficially owned by them, directly or indirectly, by six months after the expiry of the original lock-up period. The extended lock-up period runs from 8 October 2026 to 7 April 2027, inclusive of both dates.

The relevant shares refer to: (1) 15,677,400 H shares and 10,451,600 unlisted shares held by Dr. Liang Wenqing through Suzhou Lingtou Investment Management Enterprise (Limited Partnership), which is controlled by him; (2) 14,378,700 H shares and 9,585,800 unlisted shares held by Dr. Li Li through Suzhou Meizhongrui Investment Management Enterprise (Limited Partnership), which is controlled by her; and (3) a total of 7,563,300 shares in which Dr. Liang Wenqing and Dr. Li Li respectively hold interests through Suzhou Lingtou and Suzhou Meizhongrui in the company's employee incentive platform (these shares do not belong to the company's 2024 share incentive plan).

The company believes that the voluntary undertakings made by the core management are based on their confidence in the group's long-term development strategy, business prospects, and ability to continuously create value, and reflect their commitment to aligning with the long-term interests of the company and all shareholders. The undertakings were made voluntarily and without compensation by the core management.